The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.


Bravo Vergel, Y; Hawkins, NS; Claxton, K; Asseburg, C; Palmer, S; Woolacott, N; Bruce, IN; Sculpher, MJ; (2007) The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology (Oxford, England), 46. pp. 1729-35. ISSN 1462-0324 DOI: https://doi.org/10.1093/rheumatology/kem221

Full text not available from this repository.

Abstract

OBJECTIVE: Tumour necrosis factor (TNF) antagonists have been shown to improve the outcomes in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). We assess the cost-effectiveness of two TNF antagonists and so-called 'palliative care' for the treatment of active PsA from the perspective of the UK National Health Service (NHS).

Item Type: Article
Keywords: Adult, Antibodies, Antirheumatic Agents, Antirheumatic Agents: economics, Antirheumatic Agents: therapeutic use, Arthritis, Bayes Theorem, Clinical Trials, Cost-Benefit Analysis, Drug Costs, Drug Costs: statistics & numerical data, Female, Humans, Immunoglobulin G, Immunoglobulin G: economics, Immunoglobulin G: therapeutic use, Male, Middle Aged, Monoclonal, Monoclonal: economics, Monoclonal: therapeutic use, Palliative Care, Palliative Care: economics, Phase III as Topic, Psoriatic, Psoriatic: drug therapy, Psoriatic: economics, Receptors, State Medicine, State Medicine: economics, Treatment Outcome, Tumor Necrosis Factor, Tumor Necrosis Factor-alpha, Tumor Necrosis Factor-alpha: antagonists & inhibit, Tumor Necrosis Factor: therapeutic use, Adult, Antibodies, Monoclonal, economics, therapeutic use, Antirheumatic Agents, economics, therapeutic use, Arthritis, Psoriatic, drug therapy, economics, Bayes Theorem, Clinical Trials, Phase III as Topic, Cost-Benefit Analysis, Drug Costs, statistics & numerical data, Etanercept, Female, Humans, Immunoglobulin G, economics, therapeutic use, Infliximab, Male, Middle Aged, Palliative Care, economics, Receptors, Tumor Necrosis Factor, therapeutic use, State Medicine, economics, Treatment Outcome, Tumor Necrosis Factor-alpha, antagonists & inhibitors
Faculty and Department: Faculty of Public Health and Policy > Dept of Health Services Research and Policy
PubMed ID: 17956918
URI: http://researchonline.lshtm.ac.uk/id/eprint/2535079

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
94Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item